MX366829B - Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. - Google Patents
Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.Info
- Publication number
- MX366829B MX366829B MX2015000179A MX2015000179A MX366829B MX 366829 B MX366829 B MX 366829B MX 2015000179 A MX2015000179 A MX 2015000179A MX 2015000179 A MX2015000179 A MX 2015000179A MX 366829 B MX366829 B MX 366829B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- same
- dosage forms
- compositions
- itraconazole
- Prior art date
Links
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 title abstract 2
- 229960004130 itraconazole Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902624A AU2012902624A0 (en) | 2012-06-21 | Itraconazole formulations and uses | |
| PCT/US2013/047135 WO2013192566A1 (en) | 2012-06-21 | 2013-06-21 | Itraconazole compositions and dosage forms, and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015000179A MX2015000179A (es) | 2016-02-16 |
| MX366829B true MX366829B (es) | 2019-07-25 |
Family
ID=49769445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015000179A MX366829B (es) | 2012-06-21 | 2013-06-21 | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US8921374B2 (https=) |
| EP (1) | EP2863911A4 (https=) |
| JP (2) | JP2015531749A (https=) |
| KR (3) | KR20200065093A (https=) |
| CN (2) | CN104507480A (https=) |
| AU (3) | AU2013278001A1 (https=) |
| BR (1) | BR112014031706A8 (https=) |
| CA (1) | CA2876909C (https=) |
| HK (1) | HK1207288A1 (https=) |
| MX (1) | MX366829B (https=) |
| WO (1) | WO2013192566A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014031706A8 (pt) | 2012-06-21 | 2021-10-19 | Mayne Pharma Int Pty Ltd | Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| US11390613B2 (en) | 2017-08-20 | 2022-07-19 | University Of Connecticut | Azole analogues and methods of use thereof |
| AU2019277362A1 (en) * | 2018-05-30 | 2021-01-21 | Mayne Pharma International Pty Ltd | Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome |
| WO2021030174A1 (en) | 2019-08-09 | 2021-02-18 | University Of Connecticut | Truncated itraconazole analogues and methods of use thereof |
| CN115768779A (zh) * | 2020-05-07 | 2023-03-07 | 上海偕怡医药科技有限公司 | 伊曲康唑前药及其用途 |
| WO2023007514A1 (en) * | 2021-07-29 | 2023-02-02 | Dr. Reddy's Laboratories Limited | Improved oral bioavailable pharmaceutical compositions |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3110794B2 (ja) | 1991-06-05 | 2000-11-20 | ユーシービージャパン株式会社 | １，４−ジヒドロピリジン誘導体を含有する製剤 |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| PH30929A (en) * | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
| US6254889B1 (en) | 1995-07-26 | 2001-07-03 | Kyowa Hakko Kogyo Co., Ltd. | Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer |
| ATE255883T1 (de) | 1996-05-20 | 2003-12-15 | Janssen Pharmaceutica Nv | Fungizide mittel mit verbesserter bioverfügbarkeit |
| DE69730241T2 (de) | 1996-06-28 | 2005-08-11 | Schering Corp. | Feste lösung eines fungizids mit erhöhter bioverfügbarkeit |
| CA2317106C (en) | 1997-12-31 | 2004-11-23 | Choongwae Pharma Corporation | Method and composition of an oral preparation of itraconazole |
| KR100336090B1 (ko) | 1998-06-27 | 2002-05-27 | 윤승원 | 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제 |
| JP2002534371A (ja) | 1999-01-06 | 2002-10-15 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物 |
| EP1027886B1 (en) | 1999-02-10 | 2008-07-09 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
| EP2415462A1 (en) * | 1999-12-23 | 2012-02-08 | Mayne Pharma International Pty Ltd. | Improved pharmaceutical compositions for poorly soluble drugs |
| KR100425755B1 (ko) * | 2001-08-27 | 2004-04-03 | 주식회사 원진신약 | 이트라코나졸을 함유하는 조성물 및 그 제조방법 |
| KR100529766B1 (ko) * | 2003-09-09 | 2005-11-17 | 한미약품 주식회사 | 음식물 섭취에 따른 영향이 적은, 이트라코나졸경구투여용 조성물 및 이의 제조 방법 |
| US20050058670A1 (en) | 2003-09-09 | 2005-03-17 | Jong-Soo Woo | Oral itraconazole composition which is not affected by ingested food and process for preparing same |
| JP4342426B2 (ja) * | 2004-11-24 | 2009-10-14 | 科研製薬株式会社 | イトラコナゾール経口投与用製剤 |
| US8486456B2 (en) * | 2005-08-08 | 2013-07-16 | Abbott Gmbh & Co., Kg | Itraconazole compositions with improved bioavailability |
| WO2008002568A2 (en) * | 2006-06-26 | 2008-01-03 | Mutual Pharmaceutical Company, Inc. | Active agent formulations, methods of making, and methods of use |
| US20110262517A1 (en) * | 2007-04-05 | 2011-10-27 | The Johns Hopkins University | Chirally pure isomers of itraconazole and inhibitors of lanosterol 14a-demethylase for use as angiogenesis inhibitors |
| BR112014031706A8 (pt) | 2012-06-21 | 2021-10-19 | Mayne Pharma Int Pty Ltd | Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol |
-
2013
- 2013-06-21 BR BR112014031706A patent/BR112014031706A8/pt active Search and Examination
- 2013-06-21 WO PCT/US2013/047135 patent/WO2013192566A1/en not_active Ceased
- 2013-06-21 CA CA2876909A patent/CA2876909C/en active Active
- 2013-06-21 AU AU2013278001A patent/AU2013278001A1/en not_active Abandoned
- 2013-06-21 KR KR1020207015341A patent/KR20200065093A/ko not_active Ceased
- 2013-06-21 CN CN201380040270.9A patent/CN104507480A/zh active Pending
- 2013-06-21 KR KR1020217010610A patent/KR20210043721A/ko not_active Abandoned
- 2013-06-21 MX MX2015000179A patent/MX366829B/es active IP Right Grant
- 2013-06-21 KR KR20157001531A patent/KR20150043296A/ko not_active Ceased
- 2013-06-21 CN CN201811419638.3A patent/CN109674795A/zh active Pending
- 2013-06-21 EP EP13806558.6A patent/EP2863911A4/en active Pending
- 2013-06-21 HK HK15107854.3A patent/HK1207288A1/xx unknown
- 2013-06-21 JP JP2015518624A patent/JP2015531749A/ja active Pending
- 2013-06-21 US US13/924,222 patent/US8921374B2/en active Active
-
2014
- 2014-10-10 US US14/511,420 patent/US9272046B2/en active Active
-
2015
- 2015-10-14 US US14/882,662 patent/US9713642B2/en active Active
-
2017
- 2017-06-15 US US15/623,742 patent/US20170348421A1/en not_active Abandoned
-
2018
- 2018-02-22 AU AU2018201298A patent/AU2018201298B2/en active Active
- 2018-07-02 JP JP2018126027A patent/JP6757367B2/ja active Active
- 2018-11-21 US US16/198,645 patent/US10463740B2/en active Active
-
2019
- 2019-11-01 US US16/671,606 patent/US10806792B2/en active Active
-
2020
- 2020-08-14 AU AU2020217438A patent/AU2020217438A1/en not_active Abandoned
- 2020-10-19 US US17/074,497 patent/US11638758B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
| MX2015010921A (es) | Compuestos de carbazol utiles como inhibidores de bromodominio. | |
| IN2014DN10386A (https=) | ||
| PH12015501648B1 (en) | 2-aminopyrimidine derivatives for the treatment of viral infections | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| PH12016500094A1 (en) | Autotaxin inhibitors | |
| MY193728A (en) | Muscarinic receptor agonists | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| UA117032C2 (uk) | Селективний інгібітор фосфатидилінозитол-3-кінази-гамма | |
| PH12015500724A1 (en) | 1, 2, 4-triazine derivatives for the treatment of viral infections | |
| IN2013MU03583A (https=) | ||
| PH12014501991B1 (en) | Phenicol antibacterials | |
| PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| IN2015DN02912A (https=) | ||
| MX366829B (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| PH12016500495A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| MX2015016603A (es) | Composiciones de corticosteroides. | |
| MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
| WO2014122671A3 (en) | Solid oral compositions of saxagliptin | |
| IN2013MU03428A (https=) | ||
| MX2014004742A (es) | Nuevos agentes antibacterianos de fenicol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |